Aug 22, 2012: Pacific Therapeutics Completes Enrollment In Clinical Trial Of PTL-202
Aug 22, 2012: Pacific Therapeutics Initiates Clinical Trial Of PTL-202
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans
Expert Panel Validation
List of Tables
Number of Products Under Development for Bronchiolitis, H2 2012
Products under Development for Bronchiolitis – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
PARI Pharma GmbH, H2 2012
Mucosis B.V., H2 2012
APT Pharmaceuticals, Inc., H2 2012
Pacific Therapeutics Ltd., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Global Markets Direct’s, 'Bronchiolitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bronchiolitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchiolitis. Bronchiolitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
A snapshot of the global therapeutic scenario for Bronchiolitis.
A review of the Bronchiolitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Bronchiolitis pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.
Reasons to buy
Identify and understand important and diverse types of therapeutics under development for Bronchiolitis.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Bronchiolitis pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.